Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Cancer Prev Res (Phila). 2015 Dec 23;9(2):135–141. doi: 10.1158/1940-6207.CAPR-15-0299

Table 3.

Association of pre-treatment antibody levels with recurrence-free survival in patients with HPV-positive oropharyngeal cancer

Serology parameter Univariate analysis1 (n=43) Multivariable analysis2 (n=41)
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Log E1 1.01 (0.60 – 1.69) 0.982 0.97 (0.59 – 1.59) 0.912
Log E2 1.00 (0.56 – 1.79) 0.999 0.92 (0.48 – 1.73) 0.785
Log E6 5.42 (1.14 – 25.7) 0.033 7.06 (1.15 – 43.2) 0.035
Log E7 0.71 (0.32 – 1.58) 0.403 0.46 (0.16 – 1.32) 0.149
1

Cox proportional hazards model;

2

In multivariable analysis, alcohol consumption, smoking history, and TNM stage at diagnosis were adjusted for.